Wike Medical's Core Product DOCS VALVE® Listed Among Hubei’s Prestigious '61020' Sci-Tech Innovation Achievements

At the beginning of the New Year, a significant breakthrough has been reported in Hubei's scientific and technological innovation sector!1Month4On the day, the Hubei Provincial Science and Technology Innovation Conference was grandly held at Hongshan Hall, where it was officially announced on-site.2025Annual Hubei Province“61020”List of Scientific and Technological Innovation Achievements,Vickor's independently developed“Transcatheter Aortic Valve Replacement System”With hard-core technical strength and significant industrial value, successfully selected20A list of landmark innovative products, adding strong momentum to the high-quality development of Hubei's biopharmaceutical industry!

Some friends may ask,“61020”How long is the list of scientific and technological innovation achievements“Gold Content”? In fact, this system is the core approach for Hubei to build a highland of scientific and technological innovation. It focuses on national strategic needs and Hubei's advantageous fields, with three major goals targeted for breakthroughs each year.——Breakthrough6Major Basic Research, Tackling10Key core technologies, building20A landmark innovative product. To be selected for this list, the results must possess outstanding originality, leadership, and标志性, showcasing Hubei's systematic breakthroughs in key areas such as artificial intelligence, advanced manufacturing, and biomedicine. This is a true representation of Hubei's technological innovation.“Annual Hardcore Achievement Report”。

Among the many high-quality achievements,Vickor Medical's“Transcatheter Aortic Valve Replacement System”Successfully entered20Among the list of landmark innovative products, which not only represents high recognition of the product's technological innovation, but also highlights Vickor's leading position in the field of cardiovascular intervention.

As the core innovation achievement of Vickor,DOCS VALVE® The transcatheter aortic valve replacement system contains quite a few...“Black Technology”：

Relying on fully independent intellectual property rights, it has achieved significant technological breakthroughs.——Innovation covers dual indications of stenosis and regurgitation, successfully overcoming the industry's technical bottleneck of large annulus and pure regurgitation anchoring.. More noteworthy is itsIntegrated valve frame structure fusion“Three-Dimensional Dual-Curve Adjustment of the Aorta”And“Bidirectional Fixed Forward Release”Two Core Technologies, which can significantly improve the coaxial positioning accuracy of the valve and ensure the safe and stable release of the valve during the operation.

The direct advantage brought by these technological innovations isEnabling transcatheter aortic valve replacement surgery to be performed under local anesthesia and without the need for pacing has not only significantly reduced surgical trauma and risks., which updates the traditional treatment concept, provides clinical doctors with a more precise and reliable treatment tool, and also brings safer and higher-quality treatment options to numerous patients with valvular diseases.

This selection in Hubei“61020”The list of scientific and technological innovation achievements is a strong testament to Vickor's commitment to innovation-driven development. In the future, Vickor will continue to focus on the biopharmaceutical field, empowering clinical diagnosis and treatment with more groundbreaking innovations, contributing to the construction of Hubei as a highland for scientific and technological innovation, and contributing to the implementation of the Healthy China strategy!

Retracing Vickor's development path, it has been since2018Year7Since its establishment in the month of [specific month] in Wuhan's East Lake High-tech Zone, Wuhan Vickor Medical Technology Co., Ltd. has consistently focused on addressing major clinical needs in the cardiovascular field. The company has been deeply engaged in the minimally invasive interventional track for heart failure and structural heart disease, striving to create an innovative medical device platform that offers comprehensive cardiovascular solutions. By gathering multi-disciplinary talents including experts in structural heart disease interventions and metal material science, the company has formed a robust team that combines medical research and enterprise expertise, laying a solid foundation for technological innovation.

To date, Vickor has built a diversified product portfolio, covering core products such as atrial shunt devices, patent foramen ovale occluders, and transcatheter aortic valve replacement systems, while completing the upstream and downstream industrial chain layout in cities such as Wuhan, Wuxi, Suzhou, Beijing, and Shanghai. With continuous investment in innovation, the company has applied for patents.100In addition, multiple products have been awarded the national-level innovative medical device designation. The company has also successively received honors such as a high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise in Hubei Province. In terms of financing, the company has gained support from well-known institutions such as Sequoia China and Borch Capital, successfully completing multiple rounds of financing, which has provided sufficient impetus for technological research and development and the transformation of achievements.2025Year5In the month, Vickor Qi Yuan (Wuxi) officially commenced operations, marking a new phase in the company's innovative layout in the Yangtze River Delta region, and accelerating progress.“Made in China”Going Global.